ReviewAmerican journal of translational research2026
Efficacy and safety of Xuebijing combined with ulinastatin in the treatment of sepsis complicated by acute lung injury: a meta-analysis.
Review in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of Xuebijing injection combined with ulinastatin in patients with sepsis complicated by acute lung injury.
methodsPubMed, Web of Science, the Cochrane Library, VIP Database, China National Knowledge Infrastructure and Wanfang Database were searched from inception to January 2026. Two reviewers independently screened studies, extracted data and assessed the risk of bias using the revised Cochrane Risk-of-Bias Tool for Randomized Trials, Version 2, for randomized controlled trials (RCTs) and the Risk Of Bias In Non-randomized Studies of Interventions tool for the retrospective study. Meta-analyses were performed using R version 4.2.0.
resultsThirteen studies involving 1,158 patients (670 in the combination therapy group and 488 in the control group) were included. Compared with control therapy, Xuebijing plus ulinastatin significantly reduced TNF-α, IL-6, HMGB-1, PCT and CRP levels; improved the oxygenation index; reduced the extravascular lung water index and Acute Physiology and Chronic Health Evaluation II score and shortened mechanical ventilation duration (all P < 0.05). The total effective rate (RD 0.179, 95% CI 0.101-0.257; NNT = 5.6; P < 0.001) and 28-day survival rate (RD 0.118, 95% CI 0.002-0.234; NNT = 8.5; P = 0.047) were significantly higher in the combination group, whereas the incidence of adverse events did not differ significantly between groups (RD -0.004, 95% CI -0.049-0.042; P = 0.881). Sensitivity analyses supported the robustness of the findings.
conclusionXuebijing combined with ulinastatin may reduce inflammation, improve lung function and disease severity, shorten mechanical ventilation duration and increase response and survival rates without increasing adverse events. Owing to heterogeneity in treatment regimens and inclusion criteria, these findings require validation in large-scale, multicenter RCTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.